Cellectar Biosciences Initiates Phase 1b Trial for CLR 125 in Triple Negative Breast Cancer
Summary
Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial for CLR 125, an Auger-emitting radioconjugate, targeting refractory triple-negative breast cancer (TNBC). This marks a positive step in advancing a new drug candidate for a challenging cancer with limited treatment options. The initiation of this trial is a significant development for the micro-cap biotech, especially following its recent 10-K filing which raised substantial doubt about its ability to continue as a going concern. Progress in its clinical pipeline is crucial for the company's long-term viability and ability to attract future funding. Investors will now watch for updates on dosimetry, safety, and preliminary efficacy signals throughout 2026 as the trial progresses and additional sites are activated.
At the time of this announcement, CLRB was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $2.43 to $20.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.